Your browser doesn't support javascript.
Delivery of mRNA for regulating functions of immune cells.
Shi, Jia; Huang, Meng-Wen; Lu, Zi-Dong; Du, Xiao-Jiao; Shen, Song; Xu, Cong-Fei; Wang, Jun.
  • Shi J; School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, PR China.
  • Huang MW; School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, PR China.
  • Lu ZD; School of Medicine, South China University of Technology, Guangzhou 510006, PR China.
  • Du XJ; School of Medicine, South China University of Technology, Guangzhou 510006, PR China.
  • Shen S; School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, PR China; Shenzhen Bay Laboratory, Shenzhen 518132, PR China; Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, South China Univer
  • Xu CF; School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, PR China; Key Laboratory of Biomedical Engineering of Guangdong Province, and Innovation Center for Tissue Restoration and Reconstruction, South China University of
  • Wang J; School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, PR China; National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, PR China. Electroni
J Control Release ; 345: 494-511, 2022 05.
Article in English | MEDLINE | ID: covidwho-1838989
ABSTRACT
Abnormal immune cell functions are commonly related to various diseases, including cancer, autoimmune diseases, and infectious diseases. Messenger RNA (mRNA)-based therapy can regulate the functions of immune cells or assign new functions to immune cells, thereby generating therapeutic immune responses to treat these diseases. However, mRNA is unstable in physiological environments and can hardly enter the cytoplasm of target cells; thus, effective mRNA delivery systems are critical for developing mRNA therapy. The two mRNA vaccines of Pfizer-BioNTech and Moderna have demonstrated that lipid nanoparticles (LNPs) can deliver mRNA into dendritic cells (DCs) to induce immunization against severe acute respiratory syndrome coronavirus 2, which opened the floodgates to the development of mRNA therapy. Apart from DCs, other immune cells are promising targets for mRNA therapy. This review summarized the barriers to mRNA delivery and advances in mRNA delivery for regulating the functions of different immune cells.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanoparticles / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: J Control Release Journal subject: Pharmacology Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanoparticles / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: J Control Release Journal subject: Pharmacology Year: 2022 Document Type: Article